Baker BROS. Advisors LP Has $3.46 Million Holdings in vTv Therapeutics Inc. $VTVT

Baker BROS. Advisors LP increased its stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,314 shares of the biotechnology company’s stock after buying an additional 51,000 shares during the quarter. Baker BROS. Advisors LP owned 3.77% of vTv Therapeutics worth $3,463,000 at the end of the most recent reporting period.

vTv Therapeutics Stock Performance

Shares of VTVT opened at $33.28 on Friday. The company has a market cap of $131.12 million, a price-to-earnings ratio of -9.93 and a beta of 0.44. The stock has a fifty day moving average price of $35.93 and a two-hundred day moving average price of $29.51. vTv Therapeutics Inc. has a 52-week low of $14.00 and a 52-week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.51. The business had revenue of ($0.02) million for the quarter.

Wall Street Analysts Forecast Growth

VTVT has been the subject of several recent analyst reports. Evercore initiated coverage on vTv Therapeutics in a research note on Thursday. They set an “outperform” rating and a $44.00 price objective for the company. TD Cowen initiated coverage on shares of vTv Therapeutics in a report on Monday, January 5th. They issued a “buy” rating on the stock. BTIG Research reiterated a “buy” rating and set a $49.00 target price on shares of vTv Therapeutics in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, vTv Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $53.00.

Trending Headlines about vTv Therapeutics

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: Evercore ISI initiated coverage with an “Outperform” recommendation, providing a new institutional buy-side endorsement that can attract demand and support the share price. Evercore initiation article
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and $47 price target while raising several near-term EPS estimates (Q1–Q4 2026 and FY2026) and trimming losses for FY2027 relative to prior forecasts — a signal that the firm sees improving fundamentals in the nearer term and provides supportive analyst cover (no link available).
• Neutral Sentiment: vTv filed Q4 and full-year 2025 financial results and issued a corporate update; company results and commentary can influence sentiment depending on guidance and program milestones, so investors should review the release for pipeline/cash details. Q4/FY2025 results and corporate update
• Neutral Sentiment: Market calendars show vTv is projected to announce upcoming earnings — scheduled event risk can increase intraday volatility around the stock. Earnings projection article
• Negative Sentiment: Within the same HC Wainwright coverage notes, the firm lowered long‑range EPS assumptions (FY2028–FY2030 and FY2029 reductions), increasing projected longer-term losses. Those cuts could pressure expectations for longer-term profitability and cap upside despite near-term improvements (no link available).

vTv Therapeutics Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.